Chae Woon Hyung, Wieneke Heinrich, Dykun Iryna, Deuschl Cornelius, Köhrmann Martin, Frank Benedikt
Department of Neurology, University Hospital Essen, Essen, Germany.
Department of Cardiology and Angiology, Elisabeth Hospital, Essen, Germany.
Case Rep Neurol. 2021 Apr 12;13(1):225-232. doi: 10.1159/000515154. eCollection 2021 Jan-Apr.
In patients with atrial fibrillation, catheter ablation is suggested to reduce the mortality rate and is thus frequently performed. However, peri- and postprocedural thromboembolic complications as well as high recurrence rates of atrial fibrillation limit its advantages and require concomitant anticoagulation. With the advent of novel oral anticoagulants (NOACs), fixed dosing without routine laboratory monitoring became feasible. Nevertheless, several factors are associated with either an overdose or an insufficient drug activity of NOACs. We report on a patient with atrial fibrillation undergoing catheter ablation and cardioversion suffering from ischemic stroke despite being under oral anticoagulation. It turned out that the drug activity of the NOACs used was repeatedly insufficient in spite of regular intake and adequate dosing. In sum, drug activity controls should be taken into consideration in patients with thrombotic events despite oral anticoagulation with NOACs.
在心房颤动患者中,建议进行导管消融以降低死亡率,因此该操作经常进行。然而,围手术期和术后的血栓栓塞并发症以及心房颤动的高复发率限制了其优势,并且需要同时进行抗凝治疗。随着新型口服抗凝药(NOACs)的出现,无需常规实验室监测的固定剂量给药成为可能。尽管如此,有几个因素与NOACs的过量或药物活性不足有关。我们报告了一名接受导管消融和心脏复律的心房颤动患者,尽管接受了口服抗凝治疗,但仍发生了缺血性卒中。结果发现,尽管定期服药且剂量合适,但所用NOACs的药物活性多次不足。总之,对于尽管使用NOACs进行口服抗凝治疗仍发生血栓事件的患者,应考虑进行药物活性监测。